At least 8 years of relevant experience in investor relations, equity research, investment banking, or corporate finance, including meaningful experience in biotechnology, pharmaceuticals, or life sciences.
Strong understanding of financial reporting, valuation methodologies, and capital markets used by investment professionals.
Exceptional written and verbal communication skills, strong organization, and meticulous attention to detail and accuracy.
Ability to manage multiple priorities in a fast-paced, dynamic environment and deliver polished output under tight deadlines.
Responsibilities
Develop and execute an investor relations strategy aligned with corporate objectives, pipeline milestones, and long-term growth ambitions.
Manage the current investor relations agency and future public relations or media agency.
Serve as the day-to-day point of contact for buy-side and sell-side investors, field investor inquiries, and build relationships with current and prospective shareholders.
Partner with agencies to produce investor-facing materials, including press releases, earnings call scripts and question-and-answer preparation, investor presentations, media communications, fact sheets, and the annual report.
Partner with the executive team to prepare for and manage quarterly earnings calls, board meetings, investor conferences, medical conferences, non-deal roadshows, and research-and-development-day presentations.
Lead proactive and targeted investor outreach, including identifying and cultivating relationships with new institutional investors.
Monitor and analyze sell-side analyst research, market activity, shareholder composition, and peer and competitor developments, and deliver regular updates and insights to the executive team and Board.
Collaborate with research and development, clinical development, regulatory, legal, and corporate communications teams to ensure accurate, consistent, and compliant messaging across investor touchpoints.
Support corporate development activities, including materials related to mergers and acquisitions, partnerships, licensing deals, and capital markets transactions such as follow-on offerings.
Manage the corporate website and investor relations section.
Ensure compliance with Securities and Exchange Commission regulations, Regulation FD, and other disclosure requirements in coordination with Legal.
Build and scale the investor relations function's tools, processes, and infrastructure as the company grows.
Desired Qualifications
Experience at a publicly traded biotechnology or pharmaceutical company, including direct experience supporting earnings calls, roadshows, and Securities and Exchange Commission reporting cycles.
Scientific fluency and comfort engaging with clinical and regulatory content, with the ability to translate complex science into an accessible investment narrative, especially in autoimmune diseases.
Experience with investor-relations-specific tools, such as shareholder identification and customer relationship management platforms and earnings call or webcast providers.
A Master of Business Administration, Chartered Financial Analyst credential, or advanced scientific degree.
A proven track record of building relationships and influencing across all levels of an organization, including senior executives and the Board.
Salary Range: 265000 to 315000 (Currency: USD) (Pay period: per-year-salary)
Attovia Therapeutics, Inc., is seeking a Head of Investor Relations to lead our investor relations function. Reporting to the CFO, the Head of Investor Relations will play a pivotal role in shaping and executing the company's investor relations strategy. This individual will help build and articulate the company's equity narrative to the global investment community — translating complex scientific, clinical, and business information into clear, compelling communications that build trust and credibility with investors and analysts.
Key Responsibilities
Develop and execute a comprehensive investor relations strategy aligned with the company's corporate objectives, pipeline milestones, and long-term growth ambitions
Manage the company’s current investor relations agency and future public relations/media agency
Serve as a day-to-day point of contact for the buy-side and sell-side investment community, fielding inquiries and building relationships with current and prospective shareholders
Partner with agencies to manage the production of investor-facing materials, including all press releases, earnings call scripts and Q&A prep, investor presentations, media communications, fact sheets, and the annual report
Partner with executive team to prepare for and manage quarterly earnings calls, board meetings, investor conferences, medical conferences, non-deal roadshows and R&D-day presentations
Lead proactive and targeted investor outreach, including identifying and cultivating relationships with new institutional investors
Monitor and analyze sell-side analyst research, market activity, shareholder composition, and peer/competitor developments; deliver regular updates and insights to executive team and the Board
Collaborate cross-functionally with R&D, clinical development, regulatory, legal, and corporate communications to ensure accurate, consistent, and compliant messaging across all investor touchpoints
Support corporate development activities, including materials related to M&A, partnerships, licensing deals, and capital markets transactions (e.g., follow-on offerings)
Manage corporate website including investor relations section
Ensure compliance with SEC regulations, Regulation FD, and other disclosure requirements in coordination with Legal
Help build out and scale the IR function's tools, processes, and infrastructure as the company grows
Basic Qualifications
Bachelor's degree required; MBA, CFA, or advanced scientific degree a plus 8+ years of relevant experience in investor relations, equity research, investment banking, or corporate finance, with a meaningful portion of that experience in biotech, pharma, or life sciences
Experience at a publicly traded biotech/pharmaceutical company strongly preferred; direct experience supporting earnings calls, roadshows, and SEC reporting cycles
Strong understanding of financial reporting, valuation methodologies, and capital markets used by investment professionals
Exceptional written and verbal communication skills, highly organized with meticulous attention to detail and accuracy
Strategic thinker who can manage multiple priorities in a fast-paced, dynamic environment and deliver polished output under tight deadlines
Preferred Qualifications
Scientific fluency — comfort engaging with clinical and regulatory content, with the ability to translate complex science into an accessible investment narrative, especially in autoimmune diseases
Experience with IR-specific tools (e.g., shareholder ID/CRM platforms, earnings call/webcast providers) a plus
Proven track record building relationships and influencing across all levels of an organization, including senior executives and the Board
Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Our product candidates are internally discovered using our proprietary ATTOBODY™ platform, an evolution-driven, high-throughput biologics platform that enables the rapid discovery and creation of diverse biparatopic complex biologics. Our pipeline spans chronic pruritic diseases, inflammatory skin diseases, inflammatory bowel disease, and other immune-mediated conditions.
Our values define how we make decisions, work with one another, and pursue our mission:
Integrity: We put patients first, uphold the highest ethical standards, and communicate with honesty and transparency
Learning & Growth: We ask questions, challenge the status quo, seek and provide constructive feedback, and invest in the development of ourselves and others
Drive for Excellence: We set ambitious goals, take ownership, honor our commitments, move with urgency, and deliver rigorous, high-quality, and data-driven work
Innovation: We pursue transformative science, think creatively, and do more with less through resourcefulness and continuous improvement
Teamwork & Collaboration: We communicate openly, debate constructively, mentor and learn from one another, and recognize that our strongest results come from working together
We take pride in fostering a strong team and dynamic work environment, and we are seeking individuals who align with our values and contribute to a positive and impactful workplace.
Attovia is located in San Carlos, CA.
Attovia is an equal opportunity employer. We consider all qualified applicants for employment without regard to race, color, ancestry, national origin, religion or creed, age, sex, pregnancy, childbirth, breastfeeding or related medical conditions, sexual orientation, gender, gender identity or gender expression, marital status, medical condition, genetic information, physical or mental disability, military or veteran status, reproductive health decision-making, or any other characteristic protected by applicable federal, state, or local law.
The Attovia talent acquisition program is managed through internal resources, and unsolicited referrals and resumes are not accepted from employment agencies, unless advance written authorization is granted from the Human Resources department. Attovia shall not be liable for any fees arising from any unsolicited or unauthorized candidate information received relative to position vacancies.
Attovia Therapeutics, a clinical-stage biopharmaceutical company developing treatments for immune-mediated diseases, listed on Nasdaq on 5 August 2026. The Shanghai-based company issued shares at $17.00 each, opening at $21.00, with a market capitalisation of approximately $904 million.
Founded in 2023, Attovia develops biotherapeutics using its ATTOBODY platform, licensed from Alamar Biosciences. The platform enables rapid discovery of monospecific, bispecific and trispecific biologics. The company has nominated three product candidates: ATTO-1310, ATTO-2306 and ATTO-1091.
IPO proceeds will fund clinical development of ATTO-1310 and ATTO-2306, plus research pipeline advancement. Attovia is a portfolio company of Qiming Venture Partners, which backed the firm at its early stage. Qiming manages $9.5 billion across eleven US dollar and seven RMB funds.
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the closing of its upsized initial
Attovia Therapeutics, a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases, priced its upsized initial public offering at $17.00 per share. The San Carlos-based company will sell 17,000,000 shares, generating gross proceeds of $289.0 million before underwriting costs and expenses.
Attovia has also granted underwriters a 30-day option to purchase up to 2,550,000 additional shares at the offering price. The company's common stock is expected to begin trading on the Nasdaq Global Market on 5 August 2026 under the ticker symbol "ATTO", with the offering closing on 6 August 2026.
Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets are serving as joint book-running managers, whilst LifeSci Capital acts as passive book-running manager.
Attovia Therapeutics has disclosed that Venbio Global Strategic Fund IV and Goldman Sachs-affiliated entities each hold 5% or greater stakes in the company. This follows Attovia's oversubscribed $105 million Series B financing round, led by Goldman Sachs Alternatives with participation from venBio and other investors.
Since launching in June 2023, Attovia has raised $165 million in total. The Series B proceeds will advance lead programmes ATTO-1310 and ATTO-002 through initial clinical readouts and further develop its ATTOBODY platform.
Goldman Sachs Alternatives appointed Colin Walsh to Attovia's board of directors. VenBio has been a consistent investor since Attovia's inception. The increased ownership reflects investor confidence in Attovia's pipeline and proprietary platform for developing bi-specific therapeutics targeting immune-mediated diseases.